MERCK & CO., INC.
Patent Owner
Stats
- 72 US PATENTS IN FORCE
- 5 US APPLICATIONS PENDING
- Mar 15, 2018 most recent publication
Details
- 72 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 51,756 Total Citation Count
- Feb 16, 1971 Earliest Filing
- 3,455 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
Publication #
Title
Filing Date
Pub Date
Intl Class
2017/0128,599 FOLATE-CONJUGATES AND CORRESPONDING METAL-CHELATE COMPLEXES FOR USE IN DIAGNOSTIC IMAGING AND RADIOTHERAPYNov 22, 16May 11, 17[A61K, C07F, C07D, G01N, C07B]
2010/0130,453 USE OF FOLATES FOR THE PREVENTION AND TREATMENT OF VASCULAR DISEASESJan 15, 10May 27, 10[A61K, A61P]
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
9555038 Heterocycle-substituted tetracyclic compounds and methods of use thereof for the treatment of viral diseasesDec 31, 13Jan 31, 17[A61K, C07D]
9180128 Stable pharmaceutical compositions of 5,10-methylene tetrahydrofolateJun 28, 04Nov 10, 15[A61K]
8685370 Integrin targeting agents and in-vivo and in-vitro imaging methods using the sameMar 13, 09Apr 01, 14[A61K]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2016/0030,573 STABLE PHARMACEUTICAL COMPOSITIONS OF 5,10-METHYLENETETRAHYDROFOLATEAbandonedOct 15, 15Feb 04, 16[A61K]
8637555 Tetrazole derivatives and methods of treatment of metabolic-related disorders thereofExpiredOct 29, 04Jan 28, 14[A61K, C07D]
2013/0302,825 USES OF MACROPHAGE MANNOSE RECEPTOR TO SCREEN COMPOUNDS AND USES OF THESE COMPOUNDSAbandonedSep 27, 11Nov 14, 13[G01N]
2013/0266,981 EXPRESSION OF CLASS 2 MANNOSIDASE AND CLASS III MANNOSIDASE IN LOWER EUKARYOTIC CELLSAbandonedSep 21, 12Oct 10, 13[C12P]
2013/0052,670 METHOD FOR DETECTION OF AMYLOID BETA OLIGOMERS IN A FLUID SAMPLE AND USES THEREOFAbandonedJul 09, 12Feb 28, 13[G01N]
2012/0231,497 SELECTIVE ENZYMATIC HYDROLYSIS OF C-TERMINAL TERT-BUTYL ESTERS OF PEPTIDESAbandonedMay 17, 12Sep 13, 12[C12P, C07K]
2012/0213,728 GRANULOCYTE-COLONY STIMULATING FACTOR PRODUCED IN GLYCOENGINEERED PICHIA PASTORISAbandonedOct 25, 10Aug 23, 12[A61K, C12P, C12N]
8242150 Triazole derivatives for treating alzheimer'S disease and related conditionsExpiredJun 09, 08Aug 14, 12[A61K, C07D]
2012/0004,222 CB2 RECEPTOR LIGANDS FOR THE TREATMENT OF PAINAbandonedAug 18, 08Jan 05, 12[A61K, C07D, A61P]
2011/0286,916 GENERATION AND CHARACTERIZATION OF ANTI-NOTCH ANTIBODIES FOR THERAPEUTIC AND DIAGNOSTIC USEAbandonedNov 16, 09Nov 24, 11[A61K, C12N, G01N, A61P, C07K]
2011/0286,921 18F-LABELLED FOLATES AS PET RADIOTRACERSAbandonedOct 12, 09Nov 24, 11[A61K, C07D, G01N]
2011/0288,154 RNA Interference Mediated Inhibition of Epithelial Sodium Channel (ENaC) Gene Expression Using Short Interfering Nucleic Acid (siNA)AbandonedNov 18, 09Nov 24, 11[A61K, C07H, A61P]
2011/0171,729 Method for Producing Stable Mammalian Cell Lines Producing High Levels of Recombinant ProteinsAbandonedMay 03, 07Jul 14, 11[C12N]
2011/0003,862 3-Animopyraolines for Treatment of Neurodegenerative and Psychiatric DiseasesAbandonedFeb 15, 07Jan 06, 11[A61K, C07D, A61P]
7814721 Double fret-shaped improved sheath for laying floors and/or linings with tiles, parquet, moquette, wall-paper, panel coatings and the like, as well as their quick pulling away in case of their replacementExpiredOct 05, 04Oct 19, 10[E04D]
2010/0261,741 Quinazolinone T-Type Calcium Channel AntagonistsAbandonedJun 28, 10Oct 14, 10[A61K, C07D, A61P]
2010/0240,647 Treatment of Alzheimer's Disease and Related ConditionsAbandonedJan 23, 07Sep 23, 10[A61K, C07D, A61P]
Top Inventors for This Owner
Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.